Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias

NCT00061763 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

175

Enrollment

INDUSTRY

Sponsor class

Conditions

Beta-thalassemia
Myelodysplastic Syndromes
Fanconi Syndrome
Anemia, Diamond-Blackfan
Anemia, Aplastic

Interventions

DRUG: Deferasirox

Sponsor

Novartis Pharmaceuticals